Evidence map›Paper›PMID 24595664›Full record

ArticlePurinergic signalling2014

The role of activated adenosine receptors in degranulation of human LAD2 mast cells.

Chi Ting Leung, Ang Li, Juni Banerjee, Zhan-Guo Gao, Taku Kambayashi, Kenneth A Jacobson, Mortimer M Civan

Open access · bronzeAbstract read
In one paragraph

Article in Purinergic signalling, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
3.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Journal of medicinal chemistry · 2023
    Article
  5. Selective AACS medicinal chemistry letters · 2022
    Article
  6. Therapeutic Potential of Highly Selective AMolecules (Basel, Switzerland) · 2022
    Review
  7. AEuropean journal of medicinal chemistry · 2022
    Article
  8. Review
  9. Adenosine Signaling in Mast Cells and Allergic Diseases.International journal of molecular sciences · 2021
    Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. AMedicinal research reviews · 2018
    Review
  15. Pathological overproduction: the bad side of adenosine.British journal of pharmacology · 2017
    Review
  16. Review
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Chi Ting LeungDepartment of Physiology, University of Pennsylvania School of Medicine, A303 Richards Building, Philadelphia, PA, 19104-6085, USA.
Ang Li
Juni Banerjee
Zhan-Guo Gao
Taku Kambayashi
Kenneth A Jacobson
Mortimer M Civan
University of Pennsylvania · USNational Institutes of Health · US

Funding

Scientific TransparencyP30EY001583 · NEI · UNIVERSITY OF PENNSYLVANIA · PI CLAIRE H MITCHELL · 1985 to 2026
$19.5M
Development Of Drugs Acting At Adenosine ReceptorsZIADK031117 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI JACOBSON, KENNETH ALAN · 2009 to 2025
$10.4M
Aqueous Humor Outflow Control and Intraocular PressureR01EY013624 · NEI · UNIVERSITY OF PENNSYLVANIA · PI CIVAN, MORTIMER MORDECAI · 2001 to 2013
$5.6M
The role of the T cell receptor in regulatory T cell homeostasis and expansionR01HL111501 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI KAMBAYASHI, TAKU · 2012 to 2020
$3.6M
Intramural NIH HHS ZIA DK031117NEI NIH HHS EY01583NEI NIH HHS EY13624NEI NIH HHS P30 EY001583NEI NIH HHS R01 EY013624NHLBI NIH HHS R01 HL111501
6 · The paper itself

Abstract

Mast cell degranulation triggers hypersensitivity reactions at the body-environment interface. Adenosine modulates degranulation, but enhancement and inhibition have both been reported. Which of four adenosine receptors (ARs) mediate modulation, and how, remains uncertain. Also uncertain is whether adenosine reaches mast cell ARs by autocrine ATP release and ecto-enzymatic conversion. Uncertainties partly reflect species and cell heterogeneity, circumvented here by focusing on homogeneous human LAD2 cells. Quantitative PCR detected expression of A2A, A2B, and A3, but not A1, ARs. Nonselective activation of ARs with increasing NECA monotonically enhanced immunologically or C3a-stimulated degranulation. NECA alone stimulated degranulation slightly. Selective AR antagonists did not affect C3a-stimulated degranulation. NECA's enhancement of C3a-triggered degranulation was partially inhibited by separate application of each selective antagonist, and abolished by simultaneous addition of antagonists to the three ARs. Only the A2A antagonist separately inhibited NECA's enhancement of immunologically stimulated degranulation, which was abolished by simultaneous addition of the three selective antagonists. Immunological or C3a activation did not stimulate ATP release. NECA also enhanced immunologically triggered degranulation of mouse bone marrow derived mast cells (BMMCs), which was partially reduced only by simultaneous addition of the three antagonists or by the nonselective antagonist CGS15943. BMMCs also expressed A2A, A2B, and A3 ARs. but not A1AR detectably. We conclude that (a) A1AR is unnecessary for LAD2 degranulation or AR enhancement; (b) A2A, A2B, and A3 ARs all contribute to pharmacologic AR enhancement of LAD2 and BMMC degranulation; and (c) LAD2 cells depend on microenvironmental adenosine to trigger AR modulation.

Indexed as

AnimalsCell LineHumansMast CellsMiceMice, Inbred BALB CPurinergic P1 Receptor AntagonistsQuinazolinesReceptors, Purinergic P1Triazoles9-chloro-2-(2-furyl)-(1,2,4)triazolo(1,5-c)quinazolin-5-iminePurinergic P1 Receptor AntagonistsQuinazolinesReceptors, Purinergic P1Triazoles

Identifiers

PMID24595664
PMCPMC4152452
OpenAlexW2010331061

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.